^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    irinotecan

    i
    Other names: CPT-11, CPT 11, DQ 2805, IHL-305, SN 38B11, U 101440E
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase I inhibitor
    Related drugs:
    4d
    ACCELERATE: Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, British Columbia Cancer Agency | Not yet recruiting --> Recruiting
    Enrollment open
    |
    oxaliplatin • irinotecan
    4d
    A multiple-responsive nano-prodrug combining chemo-differentiation-cancer stem cell inhibition toward triple-negative breast cancer. (PubMed, Biomater Sci)
    This system co-delivers irinotecan (IRI), all-trans retinoic acid (ATRA), and CPUL119 via (1) a hypoxia-responsive prodrug (PAC: PEG2k-Azo-CPUL119) and (2) a pH/esterase-responsive conjugate (AI: ATRA-IRI)...In vivo, they achieved optimal tumor suppression and BCSC elimination in xenografts with negligible systemic toxicity. This nanoprodrug platform offers straightforward synthesis, high drug-loading capacity, and potent dual-action efficacy against bulk tumor cells and BCSCs, presenting a promising advanced breast cancer therapy.
    Journal
    |
    CD24 (CD24 Molecule)
    |
    irinotecan
    5d
    Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=56, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    oxaliplatin • irinotecan • Yutuo (zimberelimab) • leucovorin calcium • fluorouracil topical • quemliclustat (AB680)
    5d
    The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancer. (PubMed, Oncologist)
    The TOMOX-Bev combination is a feasible second-line mCRC treatment with an acceptable toxicity profile. Recruitment failure prevents efficacy conclusions, but TOMOX-Bev may be an alternative if fluropyrimidines are contraindicated.
    P2 data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Tomudex (raltitrexed)
    5d
    CIRCULATEIII: Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test (clinicaltrials.gov)
    P3, N=2450, Not yet recruiting, UNICANCER
    New P3 trial • Circulating tumor DNA
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    6d
    ARIEL-ENGIC: Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status (clinicaltrials.gov)
    P4, N=280, Not yet recruiting, Gruppo Oncologico del Nord-Ovest | Initiation date: Nov 2025 --> Apr 2026
    Trial initiation date
    |
    EREG (Epiregulin)
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    6d
    Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) (clinicaltrials.gov)
    P2, N=122, Not yet recruiting, Hospices Civils de Lyon
    New P2 trial
    |
    5-fluorouracil • irinotecan • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154)
    7d
    Exploratory biomarker analysis of RAS/BRAF somatic mutations and gene expression signatures for predicting treatment effects of aflibercept in the velour trial. (PubMed, NPJ Precis Oncol)
    The phase III VELOUR trial demonstrated improved outcomes with aflibercept plus FOLFIRI in patients with metastatic colorectal cancer previously treated with oxaliplatin-based regimens...Exploratory integrated analyses suggested OS benefit in RAS/BRAF wild-type iCMS2 tumours (HR 0.56, 95%CI 0.33-0.96) and a significant PFS advantage in bevacizumab-pretreated iCMS3 tumours (HR 0.41, 95%CI 0.20-0.85, q = 0.032)...These findings support integrating genomic and transcriptomic biomarkers to refine patient selection for anti-VEGF therapy, warranting validation in prospective studies. ClinicalTrials.gov number: NCT00561470, registered 15 November 2007.
    Journal
    |
    BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF mutation • BRAF wild-type • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    7d
    A Phase 2 Trial of an Extended-release siRNA Implant Targeting KRAS G12D/V in Locally Advanced Pancreatic Cancer. (PubMed, Clin Cancer Res)
    siG12D-LODER plus chemotherapy is safe, tolerable, and warrants further investigation in KRAS G12D/V-mutant LAPC.
    P2 data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • irinotecan • leucovorin calcium • siG12D LODER
    7d
    Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=35, Not yet recruiting, Roswell Park Cancer Institute | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical
    7d
    BEACON2: A Multi-Arm, Platform Trial For Relapsed Neuroblastoma (clinicaltrials.gov)
    P1/2, N=160, Recruiting, University of Birmingham
    New P1/2 trial
    |
    Avastin (bevacizumab) • irinotecan • topotecan • Qarziba (dinutuximab beta)
    8d
    5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. (clinicaltrials.gov)
    P1/2, N=27, Recruiting, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase classification: P1b --> P1/2 | N=18 --> 27 | Trial completion date: Jan 2023 --> Jan 2027 | Trial primary completion date: Dec 2022 --> Apr 2026
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation
    |
    Avastin (bevacizumab) • 5-fluorouracil • temozolomide • irinotecan • leucovorin calcium